Jorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.
An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.
Inequities in patient enrollment to cancer clinical trials has once again bubbled to the surface of cancer conversations, resulting in collaboration between clinicians to address and overcome the barriers observed
As COVID-19 alters current approaches to caring for patients with cancer, early emerging research data reinforce what practicing oncologists have been observing in their patients are at increased risk of mortality.
Immune checkpoint inhibitors blocking CTLA-4 or PD-1/PD-L1 often provide durable antitumor benefits to certain patients who respond to them; however, the percentage of responders is low, around 15% to 25%.
In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.